Latest Breaking News On - Arkin bio ventures - Page 1 : vimarsana.com

Bluejay Therapeutics Raises $182M in Series C Financing

Reunion raises over $100M to build a better psychedelic drug

BioPharma

Exicure and Bluejay sign hepatitis treatment development deal

Exicure and Bluejay Therapeutics have reached a patent licencing agreement for the development of cavrotolimod as a potential hepatitis treatment.

4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

Kriya Acquires Redpin Therapeutics

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

4Bio Capital: 4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics

Press Release 4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics 16 November 2022 London & New York - 4BIO Capital("Kriya"), a fully integrated gene

Bluejay raises $41M to bring hepatitis B drugs to clinical testing

BioPharma

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis

Auron Therapeutics Raises $48M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Arkin Holdings is going all-in on digital health

“For us, digital health was at the beginning a lot of hype with buzzwords, but over the years the family essentially decided that it is a must,” Head of Digital Health Investments at Arkin Holdings, Dr. Nadav Shimoni, told CTech